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Abstract: One of the principal hallmarks of Alzheimer’s disease (AD) is related to the aggregation
of amyloid-β fibrils in an insoluble form in the brain, also known as amyloidosis. Therefore,
a prominent therapeutic strategy against AD consists of either blocking the amyloid aggregation
and/or destroying the already formed aggregates. Natural products have shown significant
therapeutic potential as amyloid inhibitors from in vitro studies as well as in vivo animal tests. In this
study, the interaction of five natural biophenols (curcumin, dopamine, (-)-epigallocatechin-3-gallate,
quercetin, and rosmarinic acid) with amyloid-β(1–40) fibrils has been studied through computational
simulations. The results allowed the identification and characterization of the different binding
modalities of each compounds and their consequences on fibril dynamics and aggregation. It emerges
that the lateral aggregation of the fibrils is strongly influenced by the intercalation of the ligands,
which modulates the double-layered structure stability.
Keywords: molecular dynamics simulation; biophenols; natural compounds; amyloid fibrils;
Alzheimer’s disease; ligand–protofiber interactions
1. Introduction
The pathological hallmark of Alzheimer’s disease (AD) is the extracellular accumulation of
insoluble proteinaceous deposits called amyloid fibrils [1] that induce cytotoxicity. The formation
of mature amyloid fibrils (Aβ) proceeds through a nucleation-dependent process, where monomers
and oligomers aggregate together, forming β-sheet-rich protein structures. The most common fibrils
are Aβ(1–40) and Aβ(1–42), which are composed of 40 and 42 amino acids, respectively, and are
characterized by β-strand units aligned perpendicularly to the main fibril axis [2]. Destabilization and
clearance of amyloid aggregates by small molecules is one of the promising approaches towards the
development of AD therapies [3].
In recent years, epidemiological studies on the effects of the diet against AD and dementia
suggested that the high intake of flavonoids and polyphenols found in fruits and vegetables reduces
the risk of AD and cognitive impairments, and several natural molecules have been identified as
promoting cognitive health and interfering with the amyloidogenic activity in AD [4].
A detailed knowledge of how these molecules interact with Aβ fibrils is a prerequisite for the design
of new efficient drugs. Unfortunately, despite intensive research, the experimental characterization of
full-length Aβ oligomers/inhibitor complexes at a high level of resolution remains a great challenge.
Atomistic computer simulations are well-suited to provide molecular-level details of amyloid
oligomer and fibril interactions with ligands, helping in the future development and characterization
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of druggable modalities [5]. Basically, four aspects of the flavonoid–amyloid interactions have been
studied by computational methods: (1) the effect of ligands on the conformational transitions of Aβ
monomers from an initial random coil or α-helix into β-sheet structures [6,7] and ligand-mediated
conformational changes of the Aβ dimer [8] by means of replica exchange molecular dynamics
(REMD) simulations; (2) the effect of ligands on the aggregation of Aβ(17–36) using coarse-grained
simulations [9]; (3) the effect of ligands on the conformation and stability of amyloid-beta mutants [10]
by molecular dynamics (MD) simulations; (4) the preferential binding sites of ligands and their effect
on amyloid structure dynamics [11], Aβ fragments, and full-length single Aβ protofilaments [12–18]
by means of docking experiments, MD simulations, and free energy calculations.
Although recently, a few studies devoted their attention to the interaction of ligands (mainly
markers for amyloid detection [19–21]) with multiple Aβ protofilaments, to the best of our knowledge,
this aspect has not been investigated thoroughly for natural polyphenol ligands, except for curcumin [12].
In this study, the binding modalities of five natural biophenols (curcumin, dopamine,
(-)-epigallocatechin-3-gallate, quercetin, and rosmarinic acid) with single Aβ(1–40) protofilaments and
double-layer oligomer aggregates will be studied through atomistic computational simulations, in
order to explore structural changes in aggregate pathways upon binding.
First, putative binding sites on the Aβ(1–40) protofibril will be explored by replica exchange
molecular dynamics (REMD) simulations. Then, binding free energies (∆Gbind) will be computed on
the complexes to determine the thermodynamically favored binding modalities. Finally, the structural
effects caused by the binding of polyphenols to two double-layer protofilament polymorphs will
be assessed. To this goal, the determination of the stability of the sheet-to-sheet associations of the
double-layered organizations with and without the polyphenols will be computed by means of the
potential of mean force (PMF) methodology.
2. Methods
2.1. Molecular Dynamics Simulations
Molecular dynamics simulations were performed with GROMOS 54a7 force field [22].
The structural model of amyloid fibrils was retrieved from the Protein Data Bank [23] (PDB ID:
2LMN [24]). From this structure, an Aβ monomer was isolated and the missing N-terminal peptide
region of the Aβ(1–40) monomer (1DAEFRHDS8) was built using the Molefacture plugin in the VMD
package [25] as random coils as predicted by both the Jpred web server [26] and by the Modeller
package [27] for protein secondary structure assignments. Standard protonation states corresponding
to pH 7 were assigned to ionizable residues. The Aβ(1–40) protofibril was composed by repeating
10 monomeric units along its principal axis, obtaining a continuous structure 5 nm long.
The force field assigned to each ligand in their standard protonation states at pH 7 was built in the
GROMACS format [28] by using the Automated Topology Builder [29,30] web server.
The simulation box (7.5 × 9.7 × 8.0 nm) contains one Aβ(1–40) protofibril composed by repeating
10 monomeric units, with one ligand placed in a random position with respect to the fibril, and about
30,000 simple point charge water molecules [31]. Counter ions (Na+ and Cl−) were added at random
locations to neutralize the systems, with an ion concentration of 150 mM, close to the physiological value.
All the simulations were carried out at physiological temperature (310 K) and pressure of 1 bar.
The systems were first equilibrated for 2 ns in the NVT ensemble, then 10 n runs were carried out
in the NPT ensemble. The temperature was controlled using a velocity-rescaling thermostat with
a coupling time of 0.1 ps. During equilibration, the Berendsen barostat was used to control the
pressure, while during the production run, the Parrinello–Rhaman barostat was used with coupling
time of 2 ps and an isothermal compressibility of 4.5 × 10−5 bar−1, and the timestep used was
2.0 fs. The particle-mesh Ewald algorithm was used to calculate long-range electrostatics [32], with
a fourth-order cubic interpolation, a grid spacing of 0.16 nm, and a real-space cutoff of 1 nm [33].
Both Van der Waals and neighbor list cutoffs describing short-range interactions were set to 1.0 nm.
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A production run of 50 ns was used to identify the ligand binding sites (Section 2.2), whereas trajectories
of 100 ns were necessary for the computation of the stability of the different protofibril polymorphs
(Section 2.4). Data analysis was performed using the GROMACS-5.0.4 package [34].
2.2. Ligand Binding Sites
Temperature replica exchange MD (REMD) simulations were used to define the most probable
interacting sites of each compound with the Aβ(1–40) protofibrils. The temperatures used for replicas
were obtained by the work of Patriksson and van der Spoel [35] and are reported below: 300.00, 301.16,
302.32, 303.49, 304.66, 305.83, 307.01, 308.19, 309.38, 310.57, 311.76, 312.96, 314.16, 315.37, 316.57, 317.78,
319.00, 320.22, 321.44, 322.66, 323.89, 325.12, 326.36, 327.60, 328.85, 330.09, 331.34, 332.60, 333.86, 335.12,
336.39, 337.66, 338.93, 340.21.
An acceptance ratio of 20% was chosen, as previously suggested by Ngo et al. [36]. Each REMD
simulation replica was equilibrated with an NVT and an NPT ensemble with the same parameters
as for MD simulations. Then, a 50 ns run (i.e., the production run) was performed for each replica,
and exchanges between neighboring replicas were checked every 500 steps corresponding to 1 ps [36].
The 50 ns simulations were used for data analysis.
2.3. Ligand Binding Energy
The Molecular Mechanics Poisson–Boltzmann surface area (MM-PBSA) method [37] was used
to calculate the binding energy of each ligand to the protofibril. This method is based on the
single-trajectory approach. Thus, 100 snapshots collected consecutively over the course of the 50 ns
simulations, once the ligand reached a stable binding (i.e., Root Mean Square Displacement of its
center of mass <5 Å; Figure S1), were used. The binding free energy (∆Gbinding) is described as the free
energy difference between the complex, Gcomplex, and the summation of the free energy of the protein,
Gprotein, and ligand, Gligand:
∆Gbinding = Gcomplex − (Gprotein −Gligand) (1)
The free energy of each molecule is given by
G = EMM + Gsolvation − T∆S (2)
where T and S represent the temperature and entropy, respectively; and the mechanical energy, EMM,
of the solute in the gas phase is given by the summation of bond, angles, dihedrals, Van der Waals,
and electrostatic terms:
EMM = Ebond + Eangle + Edihedral + Eelectr + EVdW (3)
The solvation energy, Gsolvation, is calculated as follows:
Gsolvation = Gsurf + GPB (4)
where the nonpolar solvation term, Gsurf, is approximated on the solvent-accessible-surface area
(SASA) derived from the Shrake–Rupley numerical method [38]:
Gsurf = γSASA + β (5)
with γ = 0.0072 kcal/mol Å2 and β = 0 [39].
The term comprising the electrostatic potential between the solute and the solvent, GPB, is
calculated using the continuum solvent approximation [40] by the APBS package [41].
The entropy term, T∆S, is computed using the quasi-harmonic formula [42].
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2.4. Aβ(1–40) Oligomer Double-Layered Structures
Two possible double-layered structures were built by stacking the β-sheets of each monomer onto
each other in an antiparallel fashion [43,44], as shown in Figure 1. The C-terminal–C-terminal and
N-terminal–N-terminal interfaces were thus obtained. The intersheet distance was computed as the
distance between the centers of mass of the two β-sheets that are in contact. The amino acids that were
considered for the calculations of the center of mass are H13, H14, Q15, K16, L17, V18, F19, F20, A21,
and E22 for the N-terminal–N-terminal interface (β-1 β-sheets) (Figure 1a) and A30, I31, I32, G33, L34,
M35, V36, G37, G38, and V39 for the C-terminal–C-terminal interface (β-2 β-sheets) (Figure 1b).
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their β-1, in (a), and β-2 β-sheets, in (b). Fibrils are colored according to their secondary structures.
Amino acids at the interface are explicitly represented (color code: blue for positively charged, red for
negatively charged, and white for hydrophobic amino acid residues). Black arrows roughly represent
the intersheet distance.
In order to evaluate the influence of the ligands on the stability of the different protofibrils
polymorphs, the potential of mean force (PMF) method implemented in the GROMACS program was
used [45,46].
The backbone of protofibril (1) was restrained in its starting position, while a force increasing
with time was assigned to the center of mass of protofibril (2). Three directions were taken into
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account, as shown in Figure 2: the x-axis (i.e., outward), the y-axis (i.e., lateral), and the z-axis
(i.e., vertical). For each ligand and for both protofibril contact modes (β-1 and β-2 β-sheets), three runs
were performed, using as the starting configurations the ones at 90, 95, and 100 ns, ensuring good
sampling. The starting force used at the beginning of the simulation was 1000 kJ/mol nm2, and the
rate at which the application point of the force moves was 0.01 nm/ps.
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3. esults and iscussion
The five natural compounds studied are listed in Table 1, together with their effective
concentrations (EC50) for the formation, extension, and destabilization of preformed Aβ(1–40)
(fAβ(1–40)).
The overall in vitro activities of curcumin (CUR) and rosmarinic acid (ROSM) are similar [47].
Moreover, in vivo observations suggest that curcumin may be beneficial even after the disease has
developed, reducing the amyloid levels and plaque burden of aged ice with advanced amyloid
accumulation [48]. Quercetin (QUER) shows moderate in vitro preformed fAβ(1–40) destabilization
effects with respect to CUR [49]. (-)-Epigallocatechin-3-gallate (EGCG) is undergoing phase II–III
clinical trials as an inhibitor of Aβ fibrillogenesis. It decreases plaque burdens in the brain and reduces
soluble and insoluble preformed fAβ(1–40)s [50]. Finally, dopamine (DOPA) proved to be a potent
anti-amyloidogenic agent at all the different levels of formation, extension of amyloid fibrils, and
destabilization of preformed fAβ(1–40)s [51].
eterogeneity in the experi ental conditions (i.e., peptide concentrations, incubation condition,
and procedure of fAβ preparation) used in different laboratories or different experiments in the
same laboratory gives rise to discrepancies in effective EC50 concentrations, thus preventing a
quantitative rationalization of the observed experimental trend by means of the results of the
computational simulations. However, some interesting qualitative structure–activity relationships
could be considered, as shown in the following.
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Table 1. The effective concentrations (EC50) of the ligands studied for the formation, extension,
and destabilization of fAβ(1–40).
Compound Acronym Structure
Aβ(1–40)
Formation
(EC50) µM
Aβ(1–40)
Extension
(EC50) µM
Aβ(1–40)
Destabilization
(EC50) µM
Curcumin
diketo form CUR-di
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2. -2 -s eet c rres i  t  t e i -aci  se e ce: 31IIGLMVG37, 
3. Elbow con ecti  the two β-sh ts wit  the corresponding amino-acid sequence: 22EDVGSN27, 
4. top f the p otofibril, over the two β-sheets of the terminal Aβ(1–40) monomer (“Over”), 
5. disordered tails located at the N-terminal, 
6. end of the β-2 β-sheet, on the C-terminal (entry of the cleft). 
For each bi d ng si e, amino acids that mak  pe si tent inter ctions (in this work, an interaction 
is consi ered as persi t n  if the amin  acid re idue remains in contact with the ligand for at least 
60% of the total simu ation time) with the ligands and that co tribute more than 1 kcal/mol to the 
0.24 [49] 0.25 [49] 2.1 [49]
Rosmarinic
acid ROSM
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3.1. Putative Binding Sites and Binding Free Energies
Six main binding sites have been highlighted by mean of the REMD method applied to the
ligands considered. They are located at the surface of the protofibril:
1. β-1 β-she t corresponding to the amino-acid sequ nce: 16KLVFFAEDV24,
2. β-2 β-sheet corresponding to the amino-acid sequence: 31IIGLMVG37,
3. Elbow connecting the two β-sheets with the corresponding amino-acid sequence: 22EDVGSN27,
4. top of the protofibril, over the two β-sheets of the terminal Aβ(1–40) monomer (“Over”),
5. disordered tails located at t e N-terminal,
6. end of the β-2 β-sheet, on C (entry of the cleft).
i it , a ino acids that make pe siste t i teractions (in this work, an interaction
si r as persistent if the amino acid r sidue remains in contact with the ligand for at least 60%
of the total simulation time) with the ligands and th t contribute more than 1 kc l/mol to the binding
energy are highlighted in Figure 3. The probability of the occupancy of each site is shown in Figure 4a.
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It is interesting to note the different occupancy preferences of the two forms of curcumin. The CUR-di
form predominantly interacts with the N-terminal, whereas CUR-ke is mainly found at the β-2 site.
Multiple binding sites have been previously described in the literature for curcumin derivatives
and other related compounds. In particular, the β-2 site has been very recently targeted in a combined
computational and experimental study by Battisti et al. [15], aimed at the design of curcumin-like
amyloid beta peptide inhibitors. Binding to the N-terminal and Over positions have been observed for
curcumin and other ligands by means of site map analysis by Kundaikar et al. [52]. Moreover, the β-1
binding site has previously been suggested as a possible binding site for curcumin on the basis of
solid-state NMR experiments [53] and computational studies on the Aβ hexapeptide 16KLVFFA21 and
full-length Aβ fibrils [12,15].
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Although a few studies in the literature proposed the cavity formed by the two β-sheets and
the turn as a possible binding site for curcumin [17,18] and other compounds such as Orange-G [19],
this site is never occupied by the ligands considered in the present study. However, small portions
of the CUR-ke, EGCG, QUER, and ROSM ligands can occasionally penetrate this cavity during the
dynamic simulations runs, when they are interacting with the Aβ(1–40) protofibril in the Over position.
By considering the probability of the occupancy of each binding sites (Figure 4a) together with
the corresponding binding free energies (Figure 4b), it emerges that:
- CUR-ke, the predominant form in aqueous solution on the basis of the recent results obtained
by Manolova et al. [54], shows a strong propensity to dock at the β-2 site and realizes at this site
strong interactions (∆Gbind > −20 kcal/mol) with the fAβ(1–40) fibril. However, moderate to
strong (−10 < ∆Gbind > −20 kcal/mol) free energies of binding are found for all the binding sites,
with the exception of the N-terminal (N-ter) one.
- DOPA shows a preference for docking at the β-2 and N-ter sites. However, by considering the free
energy of binding, it does not show selectivity among the six sites studied, realizing moderate to
weak interactions (Gbind < −10 kcal/mol) with all of them.
- EGCG preferentially targets the N-ter and β-2 sites and secondarily, the Elbow and β-1 sites.
However, this ligand is able to realize strong binding with all six possible sites. The most stable
complexes (∆Gbind > −20 kcal/mol) are obtained at the β-2 and β-1 sites. The ability of EGCG to
bind to the N-terminal amino acids (residues 1–16) is confirmed by results obtained by isothermal
titration calorimetry experiments [55]. Moreover, recent findings by solution NMR indicate that
EGCG preferentially binds to Aβ oligomers and shields them at the β-1 and β-2 sites [56], where
it remodels the oligomer surface, altering the interactions with the monomers.
- QUER is found almost equally distributed between the β-1 and Over sites, with significantly
lower probability for the other sites. However, it realizes moderate binding free energies
(∆Gbind~−10 kcal/mol) in all sites, with the most stable complexes (∆Gbind~−20 kcal/mol) involving
the β-2 and β-1 sites. These results are in agreement with the finding of a computational study
recently reported by Ren et al. [13] for a structurally homologous compound, genistein. They showed
that genistein prefers to bind the β-sheet grooves to interfere with their self-aggregation.
- ROSM has higher probability for docking at the N-ter and β-1 sites, but realizes the most
stable interactions with moderate binding free energies at the β-2 and β-1 sites. Indeed, NMR
investigations suggest that a ROSM hairpin-like structure would allow the intercalation into the
Aβ oligomers structure at the interprotofilament (β−β zippers) interface [57].
Thus, taking the error in the computation of the ∆Gbind into account, it can be stated that the β-2
groove is a common structural target for all the ligands studied; at this site, the ligands realize their
most stable interactions with residues M35, G33, and I31. The β-1 site is also targeted for energetically
favored complexes, realized mainly by the interaction with the K16, V18, and F20 residues.
These regions are particularly interesting since they constitute the junction between protofilaments
in common Aβ(1–40) polymorphs [24,58]. Several recent computational studies employing different
multiple protofilament structures and a variety of ligands, used as markers for amyloid detection,
indicate the interfacial pockets at the junction between protofilaments as preferential binding
sites [19–21]. Binding of ligands at these sites can interfere with the formation or induce the disruption
of the aggregates, as discussed in the next section.
In agreement with the previous studies on related compounds [9,47], the binding free energies
obtained for these complexes are driven by more favorable nonpolar interactions rather than by
electrostatic ones (Figure S2).
Visual inspection of all MD trajectories shows that the random-coil N-terminal 1DAEFRHDS8
sequence does not appreciably alter the conformation and the usual behavior of the rest of the fibril,
despite its high flexibility, promoting the nomadism of the ligands that bind preferentially to D7 and
S8. Moreover, overall, the binding of the ligands does not disturb the structural integrity of the Aβ
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protofibrils, their overall U-shaped conformations being retained with or without interacting ligands.
The secondary structure of the Aβ monomers forming the core of the protofibrils remains unperturbed
upon ligand binding in the time length of the simulations, whereas β-sheet unfolding is observed for
the first two monomers at the top and bottom of the protofibril. This is shown in Figure 5, where the
time evolution of the Aβ(1–40) secondary structure upon EGCG binding on the β-2 β-sheet groove
is reported: chain 3 is representative of the core monomers from 3 to 8 in the simulated protofibril,
whereas chains 1 and 2 are representative of the top two (bottom two) monomers.
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Figure 5. (a) Time evolution of the Aβ(1–40) secondary structure (co puted with the GROMACS
DSSP tool) upon EGCG binding on the β-2 β-sheet groove. The perturbation induced at the monomers
lying at the head of the protofibril is highlighted by a black box. For clarity’s sake, only the top three
Aβ(1–40) monomers are shown. (b) Conformation of F19 and L34 before (left) and after (right) the
interaction of EGCG with M35.
However, in a few cases (EGCG, CUR-ke, and QUER) when the ligands, during the dynamic run,
migrate from the Over site to the β-2 β-sheet in proximity to M35, a perturbation of the fibril secondary
structure in the terminal monomers lying at the head of the protofibril is observed. This perturbation,
observed in the time of t e simulations, especially in the elb w region, induces a bend in the long fibril
axis that can impair the process of fibril elongation.
Figure 5 explains the phenomenon for the compl x formed by EGCG and the Aβ protofibrils.
The side chain of M35, interacting with the ligand, chaperones it in the search for the best nt ractions in
the β-2 groove, causing a bending of th protofibril a d altering the Aβ protofibril secondary structure
in the Elbow region. Moreover, the dynamics of the M35 side chain, induced by the interacting
ligand, disrupts the hydrophobic interaction between L34 and F19, which is found to influence a broad
range of different processes including the initiation of fibrillation, oligomer stability, fibril elongation,
and cellular toxicity [59]. In addition, it is worth underlining that M35 itself is also known to be
responsible for the hierarchical assembly of amyloid fibrils.
3.2. Influence of the Ligands o the Stability of the Aβ(1–40) Oligomer Double-Layered Structures
The effect of the ligands on the stability of the protofibril double-layered structures has been
quantified by the calculation of the forces (PMF) for protofibril(1)/ligand–protofibril(2) unbinding.
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On the basis of the binding site preferences discussed in the previous section, the intercalation of
the ligands into the C-terminal–C-terminal and N-terminal–N-terminal interfaces of the protofibrils
have been considered. Moreover, three possible ways for complex disruption have been examined by
applying the forces along the x-axis (i.e., outward shift of the protofibril(2) along its secondary axes),
the y-axis (i.e., lateral shift of the protofibril(2) along its primary axes), and the z-axis (i.e., vertical shift,
progressive removal of protofibril(2)), as shown in Figure 2.
The results are reported in Table 2, together with the force needed to separate the pristine
protofibril–protofibril aggregation, taken as the control.
It is worth noting that the C-terminal–C-terminal interface of the double-layered Aβ-sheets consists of
highly hydrophobic patches of I31, I41, and M35, with an average intermolecular distance between the two
β-sheets of ~9.1 Å (see Table 3), whereas the N-terminal–N-terminal interface consists of both hydrophobic
patches of V18 and F20 and K16–E22 salt bridges, with an average intermolecular distance of ~14.3 Å,
in agreement with previous computational studies on Aβ17–42 [60] and on different segmental polymorphs
(Aβ 35–42, Aβ 16–21, Aβ 27–32) modelled by Berhanu et al. [61]. These characteristics determine the
stability of the β-sheet–β-sheet interfaces, which is significantly higher for the N-terminal–N-terminal
arrangement with respect to the C-terminal–C-terminal one, as indicated by results from the PMF for
protofibril(1)–protofibril(2) unbinding, at least for the vertical and outward directions (Table 2).
Table 2. Computed force (expressed in kJ/mol) needed for protofibril(1)–protofibril(2) (control) and
protofibril(1)/ligand–protofibril(2) unbinding along the x, y, and z-axes.
Force Direction Lateral (x-axis) Vertical (y-axis) Outward (z-axis)
Ligand/binding site β-1 β-2 β-1 β-2 β-1 β-2
Control 2743 ± 115 2772 ± 140 3520 ± 200 2013 ± 30 3413 ± 250 2387 ± 330
CUR-di 2573 ± 40 1913 ± 110 1570 ± 70 1843 ± 35 2810 ± 10 2107 ± 140
CUR-ke 2600 ± 100 2167 ± 280 1653 ± 60 1733 ± 150 2760 ± 70 2633 ± 250
DOPA 2356 ± 95 2180 ± 190 1663 ± 55 1927 ± 420 2150 ± 95 2540 ± 90
EGCG 2968 ± 93 2407 ± 75 1967 ± 25 1610 ± 115 2570 ± 30 2533 ± 60
QUER 2493 ± 90 2043 ± 155 1726 ± 75 1720 ± 30 2553 ± 120 2650 ± 100
ROSM 2888 ± 173 1677 ± 55 2053 ± 40 1367 ± 15 2767 ± 70 2310 ± 105
Overall, the binding of the ligands to β-sheet–β-sheet interfacial pockets located between two
protofilaments produces a reduction of the stability of the protofibril dimeric structures. However,
this cannot be directly correlated to the increasing in the intermolecular distances between the
two interacting protofibrils. In fact, for the N-terminal–N-terminal interface, the distance increase upon
ligand binding is in the order of 2 Å, while for the C-terminal–C-terminal one, initially characterized
by a tight binding due to hydrophobic interactions, it is ~4–5 Å (Table 3).
Table 3. Intersheet distance in the Aβ(1–40) oligomer double-layered structures.
β-1 β-2
Control 14.3 ± 0.3 9.1 ± 0.3
CUR-di 15.7 ± 0.4 13.4 ± 0.3
CUR-ke 15.4 ± 0.3 13.6 ± 0.4
DOPA 16.5 ± 0.5 14.1 ± 0.4
EGCG 16.6 ± 0.5 13.0 ± 0.4
QUER 16.3 ± 0.4 12.7 ± 0.4
ROSM 15.8 ± 0.3 14.1 ± 0.3
On the other hand, the maximum destabilization of the double-layered Aβ-sheet aggregates is
observed for the β1-arrangements, when the forces are applied along the vertical (y), outward (z),
and lateral (x) axes, in that (descending) order.
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The binding of ligands at the C-terminal–C-terminal interface results in a moderate destabilization
of the double-layered Aβ-sheet aggregates with respect to the lateral and vertical modalities, whereas
for the outward disruption, it appears that the ligands have no effect or confer a small stabilization of
the complexes; the large errors obtained do not allow further lucubration.
It is worth noting that the intersheet separation produced by DOPA, the smallest ligand, is larger
or comparable to the one observed for more cumbersome ligands, and its effect on the destabilization
of the protofibril dimeric aggregates is also overall stronger than the other ligands.
4. Concluding Remarks
The results of the systematic computational study carried out on the interaction of five natural
biophenols with single Aβ(1–40) protofilaments by means of REMD simulations allowed the
individuation of multiple binding sites for each ligand, located at the surface of the protofibril near
to the β-1 β-sheet, β-2 β-sheet, elbow connecting the two β-sheets, top of the protofibril, disordered
N-terminal, and the C-terminal.
The REMD methodology used does not allow the biophenols to enter into the hydrophobic core
of the preformed protofibril, probably because the energy penalty associated with the penetration
process cannot be overcome using conventional MD. The absence of binding sites in the cavity of
the preformed protofibril prevents the study of destabilizing effects of the ligands by promotion of
disruption of the native backbone hydrogen bonds in the protofibril interior.
The MM-PBSA energetic analysis of the binding shows that the β-1 and β-2 binding sites
at the exposed surface of the Aβ(1–40) protofibrils, shared by all the five ligands studied, are
thermodynamically favored. At these sites, the anti-amyloid activity of biophenols consists in the
inhibition of fibril thickening and elongation.
In fact, although no significant perturbation of the overall protofibril secondary structure is
observed in the periods of time studied, interesting conformational changes of the terminal peptides
with subsequent bending of the principal axis of the protofibril are induced by ligands that migrate
during the dynamic run from the Over binding site to the β-2 binding site. This effect is more marked
for EGCG, but is observed also for CUR-ke and QUER and may preclude the association of an incoming
Aβ peptide inhibiting the fibril elongation.
Moreover, ligand binding at the β-2 binding site may inhibit the amyloidogenic process by
shielding the M35, which is responsible for the hierarchical assembly of amyloid fibrils, and disrupting
the hydrophobic interaction between L34 and F19, which is found to influence a broad range of different
processes including the initiation of fibrillation, oligomer stability, fibril elongation, and cellular toxicity.
Finally, the stability of the β-sheet–β-sheet interfaces of the Aβ(1–40) oligomer double-layered
structures is significantly affected by the intercalation of the biophenols. The force needed for
disruption of the aggregates is halved by all the ligands binding the N-terminal–N-terminal interface
when the forces are applied along the principal axis of the protofibril. The most remarkable effect is
observed for DOPA on the double-layered structure in the N-terminal–N-terminal arrangement,
whatever the force direction; whereas ROSM and EGCG exert a stronger destabilization at the
double-layered structure in the C-terminal–C-terminal arrangement.
These structural insights may serve as a molecular guide for setting up further rational drug
design in close collaboration with experimentalists in order to obtain effective inhibitors targeting fibril
formation in Alzheimer’s disease.
Supplementary Materials: The following are available online. Figure S1: Root Mean Square Deviation (RMSD)
of the center of mass of EGCG during the simulation time; Figure S2: Decomposition of free energy contributions
in the MM-PBSA calculation for each ligand tested. ∆EVdW in red, ∆Eelec in green, ∆EPB in purple, ∆ESASA in
cyan, Entropy in blue.
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